Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

CROI 2015: Retrovirus Conference Now Underway in Seattle

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place this week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com is on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

alt

Read more:

CROI 2015: Retrovirus Conference Starts Monday in Seattle

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com will be on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

alt

Read more:

Achillion's ACH-3102 + Sofosbuvir for 6 Weeks Shows 100% Cure Rate

Achillion's next-generation HCV NS5A inhibitor ACH-3102 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 6 weeks led to sustained virological response in all previously untreated genotype 1 hepatitis C patients in a small Phase 2 trial, according to a recent company announcement. Achillion now plans to test this same combination taken for just 4 weeks.

alt

Read more:

AbbVie Dual Regimen Highly Effective Against HCV Genotype 1b

A 2-drug combination consisting of AbbVie's ritonavir-boosted HCV protease inhibitor parataprevir and NS5A inhibitor ombitasvir -- part of the Viekira Pak regimen -- demonstrated a 95% cure rate for people with hepatitis C virus genotype 1b, the most common type in Japan, according to a recent company announcement.

alt

Read more:

AASLD 2014: AbbVie Next-Generation Hepatitis C Drugs Promising in Early Studies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a 3-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston.

alt

Read more: